News
GNPX
2.219
+0.43%
0.009
Weekly Report: what happened at GNPX last week (0408-0412)?
Weekly Report · 3d ago
Analysts Offer Insights on Healthcare Companies: Genprex (GNPX) and SurModics (SRDX)
TipRanks · 04/10 14:50
Genprex Earlier Reported Preclinical Data For Reqorsa Immunogene Therapy And NPRL2 Gene Therapy For Lung Cancer
Benzinga · 04/09 13:41
Weekly Report: what happened at GNPX last week (0401-0405)?
Weekly Report · 04/08 11:58
GENPREX EXPANDS CLINICAL TRIAL SITES FOR ACCLAIM-3 CLINICAL STUDY OF REQORSA® THERAPY IN COMBINATION WITH TECENTRIQ® TO TREAT SMALL CELL LUNG CANCER
Reuters · 04/03 12:31
Analysts Offer Insights on Healthcare Companies: Evaxion Biotech (EVAX), Genprex (GNPX) and 60 Degrees Pharmaceuticals, Inc. (SXTP)
TipRanks · 04/03 10:40
Genprex Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones · 04/03 10:34
Analysts Have Conflicting Sentiments on These Healthcare Companies: Evaxion Biotech (EVAX), 60 Degrees Pharmaceuticals, Inc. (SXTP) and Genprex (GNPX)
TipRanks · 04/03 10:31
HC Wainwright & Co. Reiterates Buy on Genprex, Maintains $10 Price Target
Benzinga · 04/03 10:23
Genprex Inc reports results for the quarter ended in December - Earnings Summary
Genprex Inc reports results for the quarter ended in December - Earnings Summary. The company reported a quarterly adjusted loss of $3.96 per share. The mean expectation of three analysts was for the company to report a loss of $5.93 million. Reported revenue was zero; analysts expected zero.
Reuters · 04/02 17:37
Genprex Publishes Preclinical Data With NPRL2 Gene Therapy Using Oncoprex Delivery System
Benzinga · 04/02 12:34
Weekly Report: what happened at GNPX last week (0325-0329)?
Weekly Report · 04/01 11:55
Genprex Inc <GNPX.OQ> expected to post a loss of $3.93 a share - Earnings Preview
Genprex Inc expected to post a loss of $3.93 a share - Earnings Preview. The company is expected to show change in quarterly revenue when it reports results on March 31. LSEG's mean analyst estimate for Genprex's quarterly revenue is for a loss. The average analyst rating on the shares is "buy"
Reuters · 03/29 19:07
Weekly Report: what happened at GNPX last week (0318-0322)?
Weekly Report · 03/25 11:58
Genprex Initiated at Buy by HC Wainwright & Co.
Dow Jones · 03/25 10:32
Genprex Price Target Announced at $10.00/Share by HC Wainwright & Co.
Dow Jones · 03/25 10:32
HC Wainwright & Co. Initiates Coverage On Genprex with Buy Rating, Announces Price Target of $10
Benzinga · 03/25 10:21
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 03/25 10:20
Genprex Shares Drop 12% on Latest Stock Offering to Get Proceeds of $5.8M
Genprex shares were down 12% to $2.99 in recent trading. The stock has plunged 67% since the beginning of the year and 91% in the past 12 months. The company agreed to sell common shares and warrants to purchase shares to raise $5.8 million. The gene therapy company is focused on developing therapies for cancer and diabetes.
Dow Jones · 03/20 18:35
JAGX and GNPX among Health Care movers
On the Move JAGX and GNPX among Health Care movers. S&P 500 Health Care Sector -0.52% to 1692.4. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index is down 0.67%. SCWorx Corp, XTLB, WORX, TFFP, TSHA, FEMY among health care sector gainers.
Seeking Alpha · 03/20 14:13
More
Webull provides a variety of real-time GNPX stock news. You can receive the latest news about Genprex Inc through multiple platforms. This information may help you make smarter investment decisions.
About GNPX
Genprex, Inc. is a clinical-stage gene therapy company. The Company is focused on the development of gene-based therapies for patients with unmet medical needs. The Company's lead oncology drug candidate, REQORSA Immunogen therapy drug (quaratusugene ozeplasmid), is being developed to treat non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). The active agent in REQORSA is a plasmid that expresses a tumor suppressor gene named TUSC2. REQORSA consists of the TUSC2 gene-expressing plasmid encapsulated in non-viral nanoparticles made from lipid molecules (its ONCOPREX Nanoparticle Delivery System). The Company is also using a different gene therapy delivery system in developing its pre-clinical diabetes candidates, GPX-002 and GPX-003. Its diabetes gene therapy is designed to work by transforming alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body's immune system.